Background: There are few data to compare the long-term efficacy of sirolimus-eluting stent (SES) and offpump coronary artery bypass grafting (OPCAB) for diabetic patients with multivessel disease (MVD).
oronary artery disease (CAD) is a major cause of morbidity and mortality in diabetic patients, 1,2 and those with CAD have prominent angiographic characteristics such as more extensive, diffuse coronary narrowing and multivessel disease (MVD). 3-7 Previous randomized trials have suggested that coronary artery bypass grafting (CABG) is the more preferred revascularization strategy for diabetic patients with MVD than percutaneous coronary intervention (PCI) using balloon angioplasty or bare metal stent, because of the increased need for repeat revascularization and less angina relief in patients treated with PCI. 8-10
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The recent advent of sirolimus-eluting stents (SES) has revolutionized interventional cardiology dramatically by reducing restenosis after PCI. In addition, there is growing evidence for the use of SES in various high-risk subsets, including diabetic patients. 11- 14 On the other hand, off-pump CABG (OPCAB) has also emerged as an established technique with particular benefits, such as shorter operating time, rapid recovery from surgery and lower rates of perioperative stroke. 15, 16 Recent studies report favorable outcomes at 4-5 years follow-up after OPCAB with total arterial revascularization using the bilateral internal mammary arteries. [17] [18] [19] [20] However, there are few data to compare the long-term efficacy and outcome of these advanced revascularization therapies (ie, SES and OPCAB) for diabetic patients with MVD.
In the present study, we examined and compared the 3-year clinical outcomes of PCI using SES with that of OPCAB in a "real-world" population of diabetic patients with MVD.
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Methods
Study Population
The study population consisted of 208 consecutive patients with MVD who underwent either SES implantation or OPCAB at the National Cardiovascular Center (Osaka, Japan) between August 2004 and December 2006 (SES: n=92 [SES group], OPCAB: n=116 [OPCAB group]). The decision to treat each patient by PCI or OPCAB was taken after consensus among the case cardiologists and cardiac surgeons. The following patients were excluded: those with severe congestive heart failure at the time of enrollment (New York Heart Association class III or IV), history of PCI, CABG or cardiac valve surgery, cerebrovascular events within past 6 months, left main stenosis >50% in diameter, acute ST-elevation myocardial infarction (MI), any contraindication to OPCAB or PCI, intolerance or contraindication to ticlopidine or clopidogrel, need for concomitant major surgery, and serum creatinine level >5.0 mg/dl. MVD was defined as angiographically confirmed stenosis >75% in diameter in more than 2 major epicardial vessels. A diabetic patient was defined as one previously diagnosed with diabetes mellitus, being treated by diet therapy, oral hypoglycemic drug and/or insulin. Informed consent was given by every patient before the procedures.
PCI and OPCAB
PCI was performed by implantation of only SES (Cypher, Cordis, Johnson & Johnson, Miami Lakes, FL, USA). All procedural decisions, including device selection and adjunctive pharmacotherapy, were made at the discretion of the individual PCI operator. Intravenous unfractionated heparin (10,000 IU) and intracoronary nitroglycerin (0.5 mg) were 
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administered before PCI. After stent implantation, angiographic optimization was performed by high-pressure dilatation to achieve an acceptable angiographic result. Intravascular ultrasound (IVUS) was used according to the operator's decision. Procedural success was defined as a residual stenosis <20% without major complications (ie, acute MI, need for CABG or repeat PCI, or death). All patients received 324 mg/day of aspirin for at least 24 h before the procedure. Dual antiplatelet therapy (aspirin 200 mg and ticlopidine 200 mg) was prescribed for at least 3 months to all patients treated with SES. OPCAB was performed using standard techniques with a stabilizer and an apical suction device. At least 1 internal mammary artery was used in all patients. To assess the patency of the bypass graft routine repeat angiographic study after OPCAB was performed in 90 patients (78%) while in hospital, and multislice computed tomography was performed in the remaining patients.
The complexity of CAD was quantified using the "SYNergy between PCI with TAXUS and Cardiac Surgery (SYNTAX)" score. 21 Clinical Follow-up Follow-up information for the study population was obtained during a visit to the outpatient clinic, review of the medical records or by telephone interview with the patient. Follow-up was completed for all patients (follow-up rate 100%). In the SES group, exercise test or stress scintigraphy was routinely performed at 8 or 9 months after PCI as the assessment of restenosis, whereas in the OPCAB group, stress exercise test or multislice computed tomography was performed 2 or 3 years after OPCAB. If myocardial ischemia or bypass graft stenosis was noted on initial non-invasive testing, follow-up coronary angiography was performed. The primary endpoint was defined as the occurrence of any major adverse cardiac and cerebral events (MACCE: defined as all-cause death, nonfatal MI, cerebral event (stroke or transient ischemic attack), or repeat revascularization by PCI or CABG).
MI was defined as presence of 2 or more of the following: (1) typical chest pain >20 min not relieved by nitroglycerin, (2) serial ECG recordings showing changes from baseline in the ST-T and/or Q-waves in 2 or more contiguous leads, (3) total serum creatine phosphokinase greater than twice the upper limit of normal. Repeat revascularization was defined as repeat PCI or CABG performed because of restenosis or a new stenotic lesion in the target or non-target vessel. Cerebrovascular events were defined as stroke, transient ischemic attack or reversible ischemic neurological deficits as determined by a neurologist and confirmed by imaging modalities. The occurrence of stent thrombosis was assessed according to the definition of the Academic Research Consortium. 22 The clinical and angiographic characteristics and the incidence of MACCE were compared between the 2 groups. Continuous data are expressed as mean ± SD. Comparison between the 2 groups was performed by the χ2 test (or Fisher exact test) for categorical data. Analysis of variance was performed for continuous data. Event-free survival was estimated using the Kaplan-Meier method, and differences were YAMAGATA K et al.
assessed using the log-rank test. P<0.05 was considered to be statistically significant. All analyses were performed using SPSS 15.0 for Windows (SPSS, Inc, Chicago, IL, USA).
Results
Baseline Characteristics
The demographic and baseline clinical characteristics of the patients are summarized in Table 1 . There was no significant difference between the 2 groups for the prevalence of unstable angina pectoris. On the other hand, a higher prevalence of stable angina pectoris and lower prevalence of silent myocardial ischemia was found in the SES group compared with the OPCAB group. Although the hemoglobin (Hb) A1c level was significantly higher in the OPCAB group than in the SES group, fasting blood glucose level, type of diabetic treatment and the prevalence of diabetic major vascular complications, except renal dysfunction, were similar between the 2 groups. In the SES group, usage of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins was significantly higher than in the OPCAB group. Table 2 shows the angiographic and procedural characteristics in the 2 groups. The SES group had a significantly higher prevalence of 2-vessel disease and a significantly lower prevalence of 3-vessel disease compared with the OPCAB group. The SYNTAX score was significantly higher in the OPCAB group than that in the SES group. Mean left ventricular ejection fraction and the prevalence of chronic total occlusion were similar between the 2 groups. In the SES group, the prevalence of type B2/C lesion was 65%, reference diameter was 2.5±0.5 mm, and average lesion length was 13±8 mm. The average number of implanted stents per vessel and per patient was 1.5±0.6 and 3.1±1.1, respectively. The average total stent length per patient was 63.8±20.0 mm. In the OPCAB group, total arterial revascularization using the bilateral internal mammary arteries and the radial artery was performed in 111 patients (95%). Table 3 shows the prevalence of in-hospital MACCE in the 2 groups. During the in-hospital period (≤30 days), there was no occurrence of any MACCE in the SES group, whereas 1 noncardiac death from sepsis, and 2 cases of non-fatal Q-wave MI occurred in the OPCAB group. In the OPCAB group, postoperative coronary angiography revealed occlusion of the right internal mammary artery in 3 patients, in whom SES were implanted in native coronary arteries. Although there were no perioperative cerebrovascular events in the OPCAB group, delayed cerebral infarction occurred 4-8 days after OPCAB in 3 patients (2.6%) and of them 1 had a cerebral hemorrhagic infarction at 4 days after OPCAB, 1 had type II heparin induced thrombocytopenia, and 1 had a history of paroxysmal atrial fibrillation, which appeared to be the main cause of the cerebral infarction. Consequently, the occurrence of MACCE up to 30 days was significantly higher in the OPCAB group than in the SES group (6.0% vs 0%, P=0.021).
Angiographic and Procedural Characteristics
In-Hospital Outcome
3-Year Outcome
During the follow-up period (mean 42±8 months), the rate of repeat revascularization was significantly higher in the SES group than in the OPCAB group ( Figure 1A : 21% vs 6.9%, P=0.003). Target lesion revascularization for post-SES restenosis was performed in 9 patients (9.8%), of whom 6 were treated with re-SES implantation, 1 was treated with Taxus implantation and 2 were treated with balloon angioplasty. Revascularization for new lesions because of disease progression was performed in 15 patients (13%) in the SES group: 12 patients were treated with SES implantation, 1 was treated with BMS implantation and OPCAB was performed in the remaining 2 patients. In the OPCAB group, SES were implanted for new lesions because of disease progression in 3 patients (2.6%), and in native coronaries because of graft occlusion in 2 patients (1.7%). In the SES group, definite stent thrombosis occurred in 1 patient treated with only aspirin at 1,146 days after SES implantation, and 1 case of sudden death occurred 14 months after SES implantation despite continuation of aspirin and ticlopidine. However, there were no cases of probable stent thrombosis, and no significant differences in all-cause death and non-fatal MI between the 2 groups. The average duration of dual antiplatelet therapy was 16±12 months and 48 patients (55%) in the SES group continued dual antiplatelet therapy for more than 1 year. However, there was a significantly higher occurrence of cerebrovascular events in the OPCAB group compared with the SES group (P=0.035); 6 patients had cerebral infarction because of intracervical artery stenosis with friable plaque, 1 patient had a left ventricular thrombus because of low left ventricular ejection fraction (29%) and 3 patients had a transient ischemic attack. In the SES group, 2 patients had a transient ischemic attack and 1 had a left atrial thrombus with atrial fibrillation. Finally, at the 3-year clinical followup, the prevalence of cumulative MACCE was comparable between the 2 groups ( Figure 1B : 27% vs 23%, P=0.492).
Although there were differences between the 2 groups in the Table 1 .
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use of some medications, such as angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, and statins, there were no significant differences in the occurrence of MACCE.
Subgroup Analysis
Comparison of the 2 revascularization strategies for the various subgroups revealed an equivalent benefit for SES implantation and OPCAB (Figure 2) .
Discussion
This is the first clinical study to compare a 3-year outcome and efficacy of PCI using SES with OPCAB in diabetic patients with MVD. Although repeat revascularization was more frequently needed in the SES group, and the OPCAB group had a higher incidence of cerebrovascular events both in-hospital and during the follow-up period, there were similar survival and MACCE rates between the 2 groups. In Figure 1 . Kaplan-Meier plots of (A) MACCE and (B) repeat revascularization for the SES and OPCAB groups. MACCE, major adverse cardiac and cerebrovascular events; OPCAB, off-pump coronary artery bypass surgery; SES, sirolimus-eluting stent.
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addition, this equivalent benefit between SES and OPCAB was revealed in various subgroups.
Comparison With Previous Studies
Prior randomized studies demonstrated that conventional CABG is a better revascularization strategy for diabetic patients with MVD than PCI using balloon angioplasty or bare metal stents. 8-10 Recently, Daemen et al 23 published the results of ARTS (the Arterial Revascularization Therapy Study)-II trial in diabetic patients with MVD and reported similar outcomes between SES and CABG, although they compared the results of SES with conventional CABG using extracorporeal circulation not OPCAB. Briguori et al 24 reported the superiority of OPCAB at 1-year follow-up compared with drug-eluting stents; however, multivessel stenting was performed in only 65% of patients and the follow-up period was limited to a year. Thus, to our knowledge there are no clinical trials that currently address the long-term effectiveness of SES for diabetic patients with MVD and compare this with OPCAB, the most advanced surgical revascularization technique. In the present study, longer and multiple SES were implanted than in the other studies, and multivessel stenting was performed in all the patients. Moreover, the present study investigated the outcomes of 208 patients treated with SES or OPCAB for 3 years with complete follow-up. Therefore, it is important that we found no significant differences with respect to the occurrence of 3-year cumulative MACCE between the SES and OPCAB groups of selected diabetic patients with MVD.
Repeat Revascularization
In the SES group, repeat revascularization at 3 years was performed in 19 patients (21%) and target lesion revascularization was performed in 9 patients (9.8%). Considering that the rate of target lesion revascularization of diabetic patients with MVD in the ARTS-II trial was 15% (23) , the rate in the present SES group seems lower. In the present study, IVUS was frequently used (80 patients: 92%), and recent studies have indicated the importance of IVUS for reducing restenosis, even in the DES era, 25-27 so this PCI procedural characteristic may be associated with the lower rate of target lesion revascularization in the present study.
In the OPCAB group, the rate of repeat revascularization was significantly lower than in the SES group (6.9% vs 21%, P=0.003). Because total arterial revascularization with bilateral internal mammary and radial arteries was performed in most of the patients (95%), these procedures seem to be associated with a significantly lower risk for repeat revascularization in the OPCAB group compared with the SES group. 17, 18 Although recent studies have reported the efficacy of SES for reducing repeat revascularization in diabetic patients, in the present study OPCAB was significantly superior to PCI with SES in reducing the need for repeat revascularization in advanced diabetic patients with MVD.
MACCE in the SES and OPCAB Groups
At the 3-year clinical follow-up, the incidence of all-cause death and non-fatal MI was similar between the 2 groups, whereas the incidence of cerebrovascular events was in- 
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creased in the OPCAB group. Recent studies, such as the ARTS-II trial, 23 the SYNTAX (the Synergy between PCI with Taxus and Cardiac Surgery) trial, 28 and a meta-analysis of 23 studies comparing CABG and PCI 29 reported a higher incidence of stroke in the CABG group. In the present study, a higher incidence of cerebrovascular events both in-hospital and during the follow-up period occurred in the OPCAB group. Some studies report that OPCAB leads to a postoperative hypercoagulable state because of intraoperative thrombin generation and less fibrinolytic activity. 30, 31 Because most of the patients in the OPCAB group were treated with aspirin monotherapy after surgery, this may have lead to the occurrence of in-hospital cerebrovascular events. In addition, patients in the OPCAB group had higher HbA1c levels, and there was a difference between the 2 groups in the use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, statins and dual antiplatelet therapy. In particular, 48 patients (55%) in the SES group continued dual antiplatelet therapy for more than 1 year. This difference also seem to be associated with the higher occurrence of cerebrovascular events in the OPCAB group.
Recently, there has been growing concern about the possibility of increased risk of stent thrombosis associated with the use of drug-eluting stents. 32-34 The ARTS-II trial reported that the rate of stent thrombosis (definite, probable, or possible) was 6.9% in diabetic patients with MVD. 23 In the present study, although 1 case of definite stent thrombosis occurred in the SES group (1%), the incidence of stent thrombosis (definite, probable, or possible) was lower than in the other study (2.1% vs 6.9%). In addition, any increased risk of death or MI was not be observed in the SES group compared with the OPCAB group. Longer continuation of dual antiplatelet therapy (mean, 16 months) and a higher frequency of using IVUS (92%) may lead to less occurrence of stent thrombosis. Thus, the use of SES in diabetic patients with MVD seems to be safe under the conditions of prolonged dual antiplatelet therapy and is an effective therapeutic equivalent to OPCAB.
Study Limitations
This was a non-randomized, single-center retrospective analysis, which might have introduced a significant bias in patient selection. However, the decision to perform PCI or OPCAB was individualized and taken by consensus of the referral physician, interventional cardiologist, and cardiac surgeon in all cases. In addition, King et al reported from the Emory EAST study that non-randomized registry patients had better outcomes than randomized treatment groups, suggesting individualized treatment decisions may be best and a potentially important predictor of outcome. 35 Thus, the present study reflects the contemporary "real world" of many centers regarding the revascularization treatment of diabetic patients with MVD and provides the important information about these patients.
In the SES group, there was higher usage of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and statins, which should be taken into consideration as a modifier of our results. However, the Kaplan-Meier curve revealed no significant differences in MACCE, irrespective of the usage of these drugs.
The FREEDOM (Future Revascularization Evaluation in patients with Diabetes Mellitus: Optimal Management of Multivessel disease) study, 36 designed to evaluate whether PCI with drug-eluting stents is more effective than CABG, is now beginning and will help to both evaluate the efficacy of SES and OPCAB, and define the optimal revascularization therapy for diabetic patients with MVD.
Conclusion
At 3-year clinical follow-up, although there were significant differences between the SES and OPCAB groups with respect to cerebrovascular events and repeat revascularization, the prevalence of cumulative MACCE was comparable between the 2 groups of diabetic patients with MVD. Although randomized studies with a larger number of patients and longer follow-up are needed to confirm the equivalency of SES to OPCAB in such patients, the present study provides important and valuable information about their clinical management, and suggests that PCI using SES is a reasonable therapeutic strategy.
